Hormone receptors and HER2 expression in primary breast carcinoma and corresponding lymph node metastasis: Do we need both?

Anticancer Research

Volumn 34, Issue 3, 2014, Pages 1435-1440

  Raica, Marius ^a   Cîmpean, Anca Maria ^a   Ceauşu, Raluca Amalia ^a   Fulga, Veaceslav ^b   Nica, Cristian ^a   Rudico, Lucian ^b   Saptefrati, Lilian ^b  

^a VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b Department of Histology Nicolae Testemitanu University of Medicine and Pharmacy Kishinev   (Moldova)

Author keywords

HER2; Hormone receptors; Immunohistochemistry; Lymph node metastasis; Primary breast cancer; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; ERBB2 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; CANCER PROGNOSIS; CANCER RECURRENCE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PHENOTYPE; TUMOR CELL; BREAST TUMOR; CANCER GRADING; ENZYME IMMUNOASSAY; FOLLOW UP; HER2; HORMONE RECEPTORS; LUNG CARCINOMA; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; PRIMARY BREAST CANCER; PROGNOSIS; RETROSPECTIVE STUDY; TUMOR RECURRENCE;

HER2; HORMONE RECEPTORS; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; PRIMARY BREAST CANCER; PROGNOSIS;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84899683702     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Coldman AJ and Phillips N: Breast cancer survival and prognosis by screening history. Br J Cancer 110(3): 556-559, 2014.
2. Chang SH, Pollack LM and Colditz GA: Obesity, Mortality, and Life Years Lost Associated With Breast Cancer in Nonsmoking US Women, National Health Interview Survey, 1997-2000. Prev Chronic Dis 10: 1301-1312, 2013.
3. Ham M and Moon A: Inflammatory and microenvironmental factors involved in breast cancer progression. Arch Pharm Res 36(12): 1419-1431, 2013.
4. Burton R and Bell R: The global challenge of reducing breast cancer mortality. Oncologist 18: 1200-1202, 2013.
5. Ahn SG, Lee HM, Cho SH, Lee SA , Hwang SH, Jeong J, Lee HD. Prognostic factors for patients with bone-only metastasis in breast cancer. Yonsei Med J 54: 1168-1177, 2013.
6. Lee SS, Ahn JH, Kim MK, Sym SJ, Gong G, Ahn SD, Kim SB, Kim WK: Brain metastases in breast cancer: prognostic factors and management. Breast Cancer Res Treat 111: 523-530, 2008.
7. Kim HJ, Im SA, Keam B, Kim YJ, Han SW, Kim TM, Oh DY, Kim JH, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Noh DY, Heo DS, Park IA, Bang YJ, Ha SW: Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment. J Neurooncol 106: 303-313, 2012.
8. Matsunaga S, Shuto T, Kawahara N, Suenaga J, Inomori S and Fujino H: Gamma Knife surgery for metastatic brain tumors from primary breast cancer: treatment indication based on number of tumors and breast cancer phenotype. J Neurosurg 113(Suppl): 65-72, 2010.
9. Rakha EA and Ellis IO: Modern classification of breast cancer: should we stick with morphology or convert to molecular profile characteristics. Adv Anat Pathol 18(4): 255-267, 2011.
10. Schnitt SJ: Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy. Mod Pathol 23(Suppl 2): S60-64, 2010.
11. Brisken C: Progesterone signalling in breast cancer: A neglected hormone coming into the limelight. Nat Rev Cancer 13: 385-396, 2013.
12. Jonat W, Bachelot T, Ruhstaller T, Kuss I, Reimann U and Robertson JF: Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer. Ann Oncol 24: 2543-2548, 2013.
13. Obr AE and Edwards DP: The biology of progesterone receptor in the normal mammary gland and in breast cancer. Mol Cell Endocrinol 357: 4-17, 2012.
14. Arslan C, Isik M, Guler G, Kulac I, Solak M, Turker B, Ozisik Y and Altundag K: Does androgen receptor have a prognostic role in patients with estrogen/progesterone-negative and c- ERBB-2-positive breast cancer? Am Surg 78: 992-999, 2012.
15. Shah PD, Gucalp A and Traina TA: The role of the androgen receptor in triple-negative breast cancer. Womens Health (Lond Engl) 9: 351-360, 2013.
16. Haddley K: Trastuzumab emtansine for the treatment of HER2- positive metastatic breast cancer. Drugs Today 49: 701-15, 2013.
17. Jones T, Neboori H, Wu H, Yang Q, Haffty BG, Evans S, Higgins S and Moran MS: Are breast cancer subtypes prognosticfor nodal involvement and associated with clinicopathologic features at presentation in early-stage breast cancer? Ann Surg Oncol 20: 2866-2872, 2013.
18. Falck AK, Fernö M, Bendahl PO and Rydén L: Does analysis of biomarkers in tumor cells in lymph node metastases give additional prognostic information in primary breast cancer? World J Surg 34: 1434-1441, 2010.
19. Falck AK, Fernö M, Bendahl PO and Rydén L: St Gallen molecular subtypes in primary breast cancer and matched lymph node metastases - aspects on distribution and prognosis for patients with luminal A tumours: Results from a prospective randomised trial. BMC Cancer 13: 558, 2013.
20. Falck AK, Bendahl PO, Chebil G, Olsson H, Fernö M and Rydén L: Biomarker expression and St. Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up. Breast Cancer Res Treat 140: 93-104, 2013.
21. Suciu C, Muresan AM, Cornea R, Suciu O, Dema A and Raica M: Semi automated evaluation of Ki 67 index in invasive ductal carcinoma of the breast. Oncol Lett 7: 107-114, 2014.
22. Allred DC, Harvey JM, Berardo M and Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11: 155-168, 1998.
23. Wolff AC, Hammond ME, Hicks DG, Dowsett M et al: Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. J Clin Oncol 31: 3997-4013, 2013.
24. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
25. Fredholm H, Eaker S, Frisell J, Holmberg L, Fredriksson I and Lindman H: Breast cancer in young women: poor survival despite intensive treatment. PLoS One 4: e7695, 2009.
26. Cummings SR, Tice JA, Bauer S, Browner WS, Cuzick J, Ziv E, Vogel V, Shepherd J, Vachon C, Smith-Bindman R, Kerlikowske K: Prevention of breast cancer in postmenopausal women: Approaches to estimating and reducing risk. J Natl Cancer Inst 101: 384-398, 2009.
27. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumors. Nature 406: 747-752, 2000.
28. Prat A and Perou CM: Deconstructing the molecular portraits of breast cancer. Mol Oncol 5: 5-23, 2011.
29. Florea AM and Busselberg D: Breast cancer and possible mechanisms of therapy resistance, J Local Global Health Sci 2: 2-9, 2013.
30. García-Becerra R, Santos N, Díaz L and Camacho J: Mechanisms of resistance to endocrine therapy in breast cancer: Focus on signaling pathways, miRNAs and genetically based resistance. Int J Mol Sci 14: 108-145, 2012.
31. Weigelt B, Glas AM, Wessels LF, Witteveen AT, Peterse JL and van't Veer LJ: Gene expression profiles of primary breast tumors maintained in distant metastases. Proc Natl Acad Sci USA 100: 15901-15905, 2003.
32. Montel V, Huang TY, Mose E, Pestonjamasp K and Tarin D: Expression profiling of primary tumors and matched lymphatic and lung metastases in a xenogeneic breast cancer model. Am J Pathol 166: 1565-1579, 2005.
33. Montel V, Mose ES and Tarin D: Tumor-stromal interactions reciprocally modulate gene expression patterns during carcinogenesis and metastasis. Int J Cancer 119: 251-263, 2006.
34. Suzuki M and Tarin D: Gene expression profiling of human lymph node metastases and matched primary breast carcinomas: Clinical implications. Mol Oncol 1: 172-180, 2007.
35. Oskarsson T: Extracellular matrix components in breast cancer progression and metastasis. Breast 22(Suppl 2): S66-72, 2013.
36. Santinelli A, Pisa E, Stramazzotti D and Fabris G: HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy. Int J Cancer 122: 999-1004, 2008
37. Niikura N, Liu J, Hayashi N, Mittendorf EA et al: Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol 30: 593-599, 2012.